Stacy A Ruse1, Philip D Harvey2, Vicki G Davis1, Alexandra S Atkins1, Kolleen H Fox3, Richard S E Keefe4. 1. NeuroCog Trials, Inc., Durham, United States. 2. University of Miami Miller School of Medicine, Miami, United States ; Miami VA Medical Center, Miami, United States. 3. Fox Evaluation and Consulting, PLLC, Holly Springs, United States. 4. NeuroCog Trials, Inc., Durham, United States ; Duke University Medical Center, Durham, United States.
Abstract
INTRODUCTION: Assessment of functional capacity is an intrinsic part of determining the functional relevance of response to treatment of cognitive impairment in schizophrenia. Existing methods are highly and consistently correlated with performance on neuropsychological tests, but most current assessments of functional capacity are still paper and pencil simulations. We developed a computerized virtual reality assessment that contains all of the components of a shopping trip. METHODS: We administered the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) to 54 healthy controls and to 51 people with schizophrenia to test its feasibility. Dependent variables for the VRFCAT included time to completion and errors on 12 objectives and the number of times that an individual failed to complete an objective. The MATRICS Consensus Cognitive Battery (MCCB) and a standard functional capacity measure, the UCSD Performance-Based Skills Assessment-Brief (UPSA-B) were administered to the patients with schizophrenia. RESULTS: Patients with schizophrenia performed more poorly than healthy controls on 10/11 of the time variables, as well as 2/12 error scores and 2/12 failed objectives. Pearson correlations for 7 of 15 VRFCAT variables with MCCB composite scores were statistically significant. CONCLUSION: These results provide support for the possibility of computerized functional capacity assessment, but more substantial studies are required.
INTRODUCTION: Assessment of functional capacity is an intrinsic part of determining the functional relevance of response to treatment of cognitive impairment in schizophrenia. Existing methods are highly and consistently correlated with performance on neuropsychological tests, but most current assessments of functional capacity are still paper and pencil simulations. We developed a computerized virtual reality assessment that contains all of the components of a shopping trip. METHODS: We administered the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) to 54 healthy controls and to 51 people with schizophrenia to test its feasibility. Dependent variables for the VRFCAT included time to completion and errors on 12 objectives and the number of times that an individual failed to complete an objective. The MATRICS Consensus Cognitive Battery (MCCB) and a standard functional capacity measure, the UCSD Performance-Based Skills Assessment-Brief (UPSA-B) were administered to the patients with schizophrenia. RESULTS:Patients with schizophrenia performed more poorly than healthy controls on 10/11 of the time variables, as well as 2/12 error scores and 2/12 failed objectives. Pearson correlations for 7 of 15 VRFCAT variables with MCCB composite scores were statistically significant. CONCLUSION: These results provide support for the possibility of computerized functional capacity assessment, but more substantial studies are required.
Authors: Christopher R Bowie; Colin Depp; John A McGrath; Paula Wolyniec; Brent T Mausbach; Mary H Thornquist; James Luke; Thomas L Patterson; Philip D Harvey; Ann E Pulver Journal: Am J Psychiatry Date: 2010-05-17 Impact factor: 18.112
Authors: Brent T Mausbach; Philip D Harvey; Ann E Pulver; Colin A Depp; Paula S Wolyniec; Mary H Thornquist; James R Luke; John A McGrath; Christopher R Bowie; Thomas L Patterson Journal: Bipolar Disord Date: 2010-02 Impact factor: 6.744
Authors: Samir Sabbag; Elizabeth M Twamley; Lea Vella; Robert K Heaton; Thomas L Patterson; Philip D Harvey Journal: Schizophr Res Date: 2011-05-26 Impact factor: 4.939
Authors: Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller Journal: Schizophr Bull Date: 2009-12-02 Impact factor: 9.306
Authors: Joseph Ventura; Tamara Welikson; Arielle Ered; Kenneth L Subotnik; Richard S E Keefe; Gerhard S Hellemann; Keith H Nuechterlein Journal: Early Interv Psychiatry Date: 2019-06-10 Impact factor: 2.732
Authors: Mor Nahum; Hyunkyu Lee; Melissa Fisher; Michael F Green; Christine I Hooker; Joseph Ventura; Joshua T Jordan; Annika Rose; Sarah-Jane Kim; Kristen M Haut; Michael M Merzenich; Sophia Vinogradov Journal: Schizophr Bull Date: 2021-01-23 Impact factor: 9.306
Authors: Philip D Harvey; Stephanie Cosentino; Rosie Curiel; Terry E Goldberg; Jeffrey Kaye; David Loewenstein; Daniel Marson; David Salmon; Keith Wesnes; Holly Posner Journal: Innov Clin Neurosci Date: 2017-02-01
Authors: A S Atkins; I Stroescu; N B Spagnola; V G Davis; T D Patterson; M Narasimhan; P D Harvey; R S E Keefe Journal: J Prev Alzheimers Dis Date: 2015-06
Authors: Richard S E Keefe; Vicki G Davis; Alexandra S Atkins; Adam Vaughan; Tom Patterson; Meera Narasimhan; Philip D Harvey Journal: Schizophr Res Date: 2016-04-16 Impact factor: 4.939
Authors: Philip D Harvey; William P Horan; Alexandra S Atkins; Heather Stevens; Matthew Welch; Joshua Yuan; Thomas L Patterson; Meera Narasimhan; Richard S E Keefe Journal: Schizophr Res Date: 2020-09-11 Impact factor: 4.939